story of the week
Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2+/HR+ Metastatic/Locally Advanced Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor-Positive Metastatic/Locally Advanced Breast Cancer: PERTAIN Final Analysis
Clin. Cancer Res 2023 Jan 30;[EPub Ahead of Print], G Arpino, J de la Haba-Rodríguez, JM Ferrero, S De Placido, CK Osborne, D Klingbiel, V Revelant, C Wohlfarth, R Poppe, MF RimawiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.